Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;109(5):441-446.
doi: 10.1111/ejh.13824. Epub 2022 Aug 9.

Low CD49d expression in newly diagnosed chronic lymphocytic leukaemia may be associated with high-risk features and reduced treatment-free-intervals

Smyth Elizabeth  1 , Kelly Aidan  2 , O' Brien David  3 , Waldron Deirdre  3 , Brophy Sarah  2 , Atkinson Emer  4 , Perera Kanthi  5 , Gerard M Crotty  5 , Walsh Aileen  5 , Connolly Michelle  5 , Clifford Ruth  6 , O'Leary Hilary  6 , Khan Ashique  6 , Christopher L Bacon  1 , Smyth Emily  7 , Anthony M McElligott  2 , Quinn Fiona  4 , Vandenberghe Elisabeth  1 , Waldron Carmel  1
Affiliations

Low CD49d expression in newly diagnosed chronic lymphocytic leukaemia may be associated with high-risk features and reduced treatment-free-intervals

Smyth Elizabeth et al. Eur J Haematol. 2022 Nov.

Abstract

This study was carried out to assess the prognostic power of low CD49d expression (≥10%) in newly diagnosed CLL patients using a previously described cohort. Eighty-five patients were included. Median age at diagnosis; 70 years (43-88); CD49d was expressed in 33/85 (38.8%); 23/33 (69.7%) at ≥30% referred to as 'HiCD49d' and 10/33 (30.3%) between 10 and 30% with a bimodal pattern on scatterplot analysis referred to as 'LoCD49d'. Eleven patients (12.9%) presented as Binet stage B, of whom 8 (72.7%) were CD49d+ (HiCD49d 7/8; LoCD49d 1/8). Seven of 81 patients (8.6%) were NOTCH1 mutated and all were CD49d+ (p ≤ .01). IgVH analysis was performed on 29 (87.8%) of the CD49d+ cases, of whom 21 (72.4%) were unmutated and 8 (27.6%) were mutated. CD38+/CD49d+ accounted for 11/20 (55%) (CD38+/HiCD49D: 9/11; CD38+/LoCD49D: 2/11). At 42 months, treatment had been initiated in 18/85 (21%) patients, of these 10/33 (30.3%) were CD49d+ versus 8/52 (15.4%) of the CD49d- group. The median treatment free interval for the CD49d+ group was 11 months (HiCD49d; 14.5 months, LoCD49d; 11 months) compared to 21.5 months for the CD49d- group. These findings suggest that the predictive value of CD49d expression is retained at expression levels down to 10%.

Keywords: CD49d; CLL; NOTCH1; bimodal; treatment-free interval.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7‐33. doi:10.3322/caac.21654 - DOI - PubMed
    1. Swerdlow S, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. IARC Publications; 2017:218‐219.
    1. Stilgenbauer S, Zenz T. Understanding and managing ultra high‐risk chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Prog. 2010;2010:481‐488. - PubMed
    1. Gaidano G, Rossi D. The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment. Hematology. 2017;2017(1):329‐337. - PMC - PubMed
    1. Kröber A, Seiler T, Benner A, et al. VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100(4):1410‐1416. doi:10.1182/blood.V100.4.1410.h81602001410_1410_1416 - DOI - PubMed